• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Qualigen Therapeutics, Inc. - Common Stock (NQ:QLGN)

    3.210 UNCHANGED
    Last Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Qualigen Therapeutics, Inc. - Common Stock

    News headline image
    Myseum (NASDAQ: MYSE) CEO Darin Myman Highlights Privacy-Driven Future of Social Media – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy
    From Faraday Future
    Via GlobeNewswire
    News headline image
    Wall Street Eyes Synergy CHC (NASDAQ: SNYR) After Power Moves to Expand FOCUSfactor® Energy Drinks in $100B+ Market – More Stocks Inside
    Via AB Newswire
    News headline image
    Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction
    From Faraday Future
    Via GlobeNewswire
    Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
    Via AB Newswire
    News headline image
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire
    News headline image
    Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
    JUPITER, FL - (NewMediaWire) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”)... 
    Via TheNewswire.com
    News headline image
    Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics to Present at LD Micro Main Event XV
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
    From Qualigen Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.